Cohan, Gary R.; Shaker-Irwin, Laurie
May 1995
Advocate;5/30/95, Issue 682, p49
Presents an answer to a query on the benefits of hormonal injections to persons suffering from anemia. Treatment of anemia by repeated blood transfusions; Emergence of the therapeutic use of recombinant human erythropoietin (EPO); Physiological action of EPO; Accomplishment of the treatment of anemia of any type.


Related Articles

  • Response and prediction of response to recombinant human erythropoietin in patients with solid tumors and platinum-associated anemia. Fjornes, T. // Journal of Oncology Pharmacy Practice;Mar1999, Vol. 5 Issue 1, p22 

    Objective. Anemia is commonly observed in tumor patients and may be worsened by the concomitant administration of chemotherapy with platinum. Recombinant human erythropoietin (rhEPO) is able to improve the chemotherapy-associated anemia and the quality of life in patients with solid tumors. The...

  • Use of Recombinant Human Erythropoietin as an Antianemic and Performance Enhancing Drug. Jelkmann, W. // Current Pharmaceutical Biotechnology;Jul2000, Vol. 1 Issue 1, p11 

    The glycoprotein hormone erythropoietin is an essential viability and growth factor for the erythrocytic progenitors in the bone marrow. Tissue hypoxia is the main stimulus for the synthesis of the hormone in the kidneys and the liver. Endogenous erythropoietin and recombinant human...

  • Recombinant erythropoietin for treatment of peguilated interferon-ribavirin induced anemia. Lopes, Susana; Macedo, Guilherme; Carvalho, Berta; Veloso, Tavarela // American Journal of Gastroenterology (Springer Nature);Sep2003 Supplement, Vol. 98, pS90 

    An abstract of the article "Recombinant Erythropoietin for Treatment of Peguilated Interferon-Ribavirin Induced Anemia," by Susana Lopes, Guilherme Macedo, Berta Carvalho and Tavarela Veloso is presented.

  • Guidelines for the Treatment of Preoperative Anaemia with Epoetin. Goodnough, L.T. // BioDrugs;1998, Vol. 10 Issue 3, p183 

    Recombinant human erythropoietin (epoetin) has been approved for use in patients undergoing autologous blood donation (ABD) in Japan, the European Union and Canada since 1993, 1994 and 1996 respectively, and for perisurgical adjuvant therapy without ABD in Canada and the US since 1996. Early...

  • Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy, and nervous system effects. Nissenson, Allen R.; Nimer, Stephen D.; Wolcott, Deane L.; Nissenson, A R; Nimer, S D; Wolcott, D L // Annals of Internal Medicine;3/1/91, Vol. 114 Issue 5, p402 

    Anemia (hematocrit less than 25%) predictably accompanies chronic renal failure and is present in over 90% of patients on chronic dialysis. Relative erythropoietin deficiency is the proximate cause. Recombinant human erythropoietin recently became available for research and clinical use....

  • Use of agents stimulating erythropoiesis in digestive diseases. López, Rosario Moreno; Aladrén, Beatriz Sicilia; García, Fernando Gomollón; Bujanda, Luis // World Journal of Gastroenterology;10/7/2009, Vol. 15 Issue 37, p4675 

    Anemia is the most common complication of inflammatory bowel disease (IBD). Control and inadequate treatment leads to a worse quality of life and increased morbidity and hospitalization. Blood loss, and to a lesser extent, malabsorption of iron are the main causes of iron deficiency in IBD....

  • The new blood doping. Schwade, Steve // Joe Weider's Muscle & Fitness;Feb92, Vol. 53 Issue 2, p54 

    States that a substance called rEPO poses dangers to athletes wanting to improve performance. Dangers; Banned by the NCAA, the International Olympic Committee and the national governing bodies of all Olympic sports; Detection of rEPO; Alternative to testing for elevated EPO; Hydration as a...

  • Novel erythropoiesis-stimulating protein. Joy, Melanie S. // Formulary;Jan2001, Vol. 36 Issue 1, p19 

    Recombinant human erythropoietin (r-HuEPO) is the gold standard for treatment of anemia related to chronic renal failure or cancer chemotherapy. However, because of its short half-life, r-HuEPO must be administered two to three times weekly in most patients. Novel erythropoiesis-stimulating...

  • Lung Cancer.  // Current Medical Literature: Respiratory Medicine;2008, Vol. 22 Issue 2, p44 

    The article presents abstracts on lung cancer which include survival after surgery in stage IA and IB non-small cell lung cancer, the implications of overdiagnosis for lung cancer screening and the association of venous thromboembolism and mortality with recombinant erythropoietin and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics